Munich Cluster for Systems Neurology
print


Breadcrumb Navigation


Content

The P2RX7 polymorphism rs2230912 is associated with depression: A meta-analysis

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Nov 7. pii: S0278-5846(17)30534-1. doi: 10.1016/j.pnpbp.2017.11.003. [Epub ahead of print]

Authors/Editors: Czamara D, Müller-Myhsok B, Lucae S.
Publication Date: 2017

12_czamara

Abstract

Various studies have investigated whether single nucleotide polymorphisms (SNPs) in the gene purinergic receptor P2X7 (P2RX7), and rs2230912 specifically, were associated with mood disorders. While some studies found positive evidence, a large number of studies reported no significant associations. In a previously published meta-analysis, Feng et al. did not find a significant association and only moderate odds ratios (ORs) in case-control studies. They reported significant findings only for family-based studies. We revisited this finding and conducted a meta-analysis including 8,652 cases and 11,153 controls, adding unpublished results from the Munich Antidepressant Response Signature (MARS) study. We found a significant association between rs2230912 and combined mood disorders (major depressive disorder (MDD) or bipolar disorder (BD)) for the allelic, dominant and heterozygous-disadvantage model, all withstanding the threshold of correction for multiple testing. Stratifying by disorder revealed significant findings for the MDD-subgroup (OR of 1.12 for the allelic model), while the BD-subgroup presented with a lower effect size (OR of 1.05) and no significance. P2RX7 encodes a purinergic receptor which is expressed in the brain and also localized in immune cells. Animal studies and functional studies will be necessary to enlighten its involvement in the etiology of mood disorders and its applicability for pharmacological purposes.

Related Links